13F Holdings
中文EN

XAGE Longevity Health Holdings, Inc.

Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics · OTC · SEC CIK 1842939 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY60.3%
TTM net income YoY5.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin59.0%
Operating margin-343.6%
Net margin-404.8%
FCF margin—
EBITDA margin-340.0%

Returns

ROE—
ROA-286.0%
ROIC (approx.)—
Asset turnover0.71x

Leverage & solvency

Liabilities / assets924.4%
Debt / equity—
Current ratio0.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-183.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.91M$50,318$0——
Cost of revenue$818,051$6,357$0——
Gross profit$1.09M$43,961$0——
R&D expense$788,888$1.05M$2.50M$2.20M—
Operating income-$7.11M-$5.00M-$5.94M-$5.51M-$467,431
Interest expense$18,214$29,446$33,527——
Pretax income-$6.87M-$10.75M-$16.21M-$9.05M-$329,382
Income tax$36,262-$97,279$0$0$0
Net income-$6.91M-$10.37M-$15.45M-$9.05M-$329,382
EBITDA-$7.03M-$4.92M-$5.85M-$5.41M—
EPS (basic)-4.83-14.56-1.46-5.47—
EPS (diluted)-4.83-14.56-1.46-5.47—
Weighted avg. shares (diluted)1.43M712,09111.02M1.76M—
Balance sheet
Cash & equivalents$706,740$157,139$2.91M$128,149$12,362
Receivables$36,500$4,096$0$0—
Inventory$963,028$108,705$0$0—
Current assets$1.95M$955,554$62.90M$605,540$973,175
PP&E, net$101,621$113,906$192,846$254,974—
Goodwill———$0—
Intangibles$15,094$19,641$24,187$28,702—
Total assets$2.37M$1.47M$63.95M$1.75M$155.42M
Current liabilities$7.92M$5.88M$38.50M$7.30M$330,007
Total liabilities$8.23M$6.19M$39.20M$8.12M$5.74M
Shareholders' equity-$5.87M-$4.71M$24.75M-$37.79M-$29.58M
Shares outstanding1.78M696,96923.09M896,580—
Cash flow statement
Operating cash flow-$3.33M-$3.89M-$8.35M-$3.43M-$451,167
Capital expenditure$14,225—$30,470$7,164—
Free cash flow-$3.34M—-$8.38M-$3.44M—
Investing cash flow-$164,225-$748,796-$30,470-$7,164—
Financing cash flow$4.04M$1.89M$11.16M$3.55M$155.67M
Depreciation & amortization$78,675$83,486$97,113$94,298—
Stock-based compensation$692,790$827,043$667,682$636,368$0
Share buybacks——$0$2,294—

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.